**ALU 201 Chapter 3 Endnotes**

Breast Cancer:

**Endnotes – Breast Cancer**

Abeloff MD, Wolff AC, et al., ”Cancer of the Breast” in Abeloff MD, Armitage JO et al, eds. *Clinical Oncology*, 3rd ed., Elsevier, Churchill Livingstone.

Siegel R, Miller KD, Jemal A, “Cancer Statistics, 2019;0:1–28.2015; 65:5-29.

Cancer Facts & Figures 2009-2010, American Cancer Society, Inc.

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975_2012/>, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

Jatoi, Ismail, Miller AB, “Why is Breast-Cancer Mortality Declining?, Lancet Oncology, 2003; 4:251-4.

Hartmann LC, Seller TA, et al., “Benign Breast Disease and the Risk of Breast Cancer”, N Engl J Med, 2005; 353:229-37.

Kawwai M, Malone KE, et al., “Active Smoking and Risk of Estrogen Receptor Positive and Triple-Negative Breast Cancer Among Women 20-44 Years of Age”, Cancer, 2014; 120:1026-1-34.

Chung MA, Wazer D, Cady B, “Contemporary Management of Breast Cancer, Obstet Gynecol Clin North Am, 2002; 29:173-88.

Harris EER Solin LJ, “The Diagnosis and Treatment of Ductal Carcinoma in Situ of the Breast”, Breast J, 2000; 6:789-95.

Schwartz GF, Terribile D, “The Treatment of Ductal Carcinoma in Situ of the Breast”, Obstet Gynecol Clin North Am, 2002; 189-200.

Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23(24):5534.

Lester SC, Cotran RS, “The Breast” in Kumar V, Abbas AK, Fausto N, eds *Robbins and Cotran Pathologic Basis of Disease*, 7th ed., Elsevier Saunders.

Friedewald SM, RaffertyEA, et al., “Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography”, JAMA, 2014; 311:2499-2507.

Hanf V, Schurtz f, et al., “AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015”, Breast Care, 2015; 10:189-197.

AJCC (American Joint Committee on Cancer) Cancer Staging Manual; 8th edition, 3rd printing, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2018.

Bundred NJ, “Prognostic and Predictive Factors in Breast Cancer”, Cancer Terat Rev, 2001; 27:137-142.

Cianfrocca M, Goldstein LJ, “Prognostic and Predictive Factors in Early-Stage Breast Cancer”, Oncologist, 2004; 9:606-16.

Soonmyung P, Shak s, et al., “A Multigene Assay to Predict Recurrence of Tamoxifen Treated, Node-Negative Breast Cancer”, N Engl J Med, 2004; 351:2817-26.

Tan LK, Giri D et al., “Occult Axillary Node Metastasis in Breast Cancer are Prognostically Significant: Results in 368 Node-Negative Patients with 20-Year Follow-Up”, J Clin Oncol, 2008; 26:1803-1809.

De Boer M, van Deurzen CHM, et al., Micrometastases of Isolated Tumor Cells and the Outcome of Breast Cancer”, N Engl J Med, 2009; 361:361:353-363.

Soerjomataram I Lourman MJ et al., “An Overview of Prognostic Factors for Long-Term Survivors of Breast Cancer”, Breast Cancer Res Treat, 2008; 107:309-330.

Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015;373(21):2005.

.

Gluz O, Liedtke C, et al., “Triple-Negative Breast Cancer – Current Status and Future Directions”, Ann Oncol, 2009; 20:1913-1927.

Banin Hirata BK, Oda JMM, et al., “Molecular markers for Breast Cancer: Prediction on Tumor Behavior”, ,Dis Markers, 2014; Epub.

Gyorffy B, Hatzis C, et al., “Multigene Prognostic Tests in Breast Cancer: Past Present Future”, Breast Cancer Res, 2015; 17:11.

Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014 Feb;110(3):565-72. Epub 2013 Dec 03.

27Mendenhall NP, “Breast-Conserving Therapy for Early-Stage Breast Cancer”, Hematol Oncol Clin North Am, 2001; 15:219-42.

28 Poggi MM, Danforth DN, et al., “Eighteen-Year Results in Treatment of Early Breast Carcinoma with Mastectomy versus Breast Conservation Therapy: The National Cancer Institute Randomized Trial”, Cancer, 2003; 98:697-702.

29 Early Breast Cancer Trialists Group, “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomized Trials”, Lancet, 2005; 365:1687-1716.

30 Kudchadkar R, O’Regan RM, “Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients with Early Stage Breast Cancer” CA Cancer J Clin, 2005; 55:145-63.

31 Baum M, Buzdar A, “The Current Status of Aromatase Inhibitors in the Management of Breast Cancer”, Surg Clin North Am, 2003; 83:973-994.

32 Joensuu H, Ejlertsen B, et al., “Aromatase Inhibitors in the Treatment of Early and Advanced Breast Cancer”, Acta Oncologica, 2005; 44:23-31.

33 Rosen PP, Groshen S, et al., “Pathological Prognostic Factors in Stage I (T10M0) and Stage II (T1N1M)) Breast Carcinoma: A Study of 44 Patients with Median Follow-p of 18 Years”, J Clin Oncol, 1989; 7:1239-1251.

34 Renner H, Hakulinen T, “Are Patients Diagnosed with Breast Cancer Before Ag 50 Years Ever Cured?, J Clin Oncol, 2004; 22:432-438.

35 Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999). National Cancer Institute, DCCPS, Surveillance Research Program. Cancer Statistics Branch. Released April 2002. Based on November 2001 Submission.

36 Joensuu H, Pylkkanen L, Toikkanen S, “Late Mortality from pT1N0M0 Breast Carcinoma”, Cancer, 199; 85:2183-9.37 Boukheris H, Rubinao C, et al., “Long-Term Mortality in a Cohort Study of 6,800 French Breast Cancer Patients Treated Between 1954 and 1983”, Acta Oncologica, 2008; 47:1122-1132.

38Levi F, Randimbison L, et al., “Long-Term Mortality of Women with a Diagnosis of Breast Cancer”, Oncology, 2002; 63:266-269.

39 Louwman WJ, Klokman WJ, et al., “Excess Mortality From Breast Cancer 20 Years After Diagnosis When Life Expectancy is Normal”, Br J Cancer, 2001; 84:700-703.

40 Taylor R, Davis P, et al., “Long-Term Survival of Women with Breast Cancer in New South Wales”, Eur J Cancer, 2003; 39:215-222.

41 Pan H, Gray R, Braybrooke J, et al. Saphner T, Tormey D, Gray R, “20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsAnnual Hazard Rates of Recurrence for Breast Cancer After Primary Therapy”, J N Engl J Med 2017;377:1836-46.Clin Oncol, 1996; 14:2378-46.

42 Yakovlev AY, Tsodikov AD, et al., “The Shape of the Hazard Function in Breast Carcinoma: Curability of the Disease Revisited”, Cancer, 1999; 85:1789-98.

Malignant Melanoma:

**Endnotes – Malignant Melanoma**

Siegel R, Miller KD, Jemal A, “Cancer Statistics, 2019”, CA Cancer J Clin, 2019;0:1–28.

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975_2012/>, based on November 2014 SEER data submission, posted to the SEER web site, April 2015..

Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: Diagnostic and therapeutic overview. *J Am Acad Dermatol*. 2001;45:260-276.

Azoury SC, Lange JR, “Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma”, Surg Clin N Am, 2014; 94:945-962.

Kraemer KH, Greene MH, Tarone R, et al. Dysplastic nevi and cutaneous malignant melanoma risk. *Lancet*. 1983;2:1076-1077.

Snels DG, Hille E, Gruis NA, Bergman W. Risk of cutaneous malignant melanoma in patients with nonfamilial atypical lesions from a pigmented lesions clinic. *J Am Acad Dermatol*. 1999;40:686-693.

Tucker MA, Melanoma Epidemiology”, Hematol Oncol Clin North Am, 2009; 23:383-397.

Carey WP, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. *Cancer*. 1994;74:3118-3125.

Clarke LE, “Dysplastic Nevi”, Clin Lab Med, 2011; 31:255-265.

Silva JH, de Sa BCS, ET AL., “Atypical Mole Syndrome and Dysplastic Nevi: Identification of Populations at Risk for Developing Melanoma – Review Article”, Clinics, 2011; 66:493-499.

Koch S, Lange JR. Amelanotic melanoma: The great masquerader. *J Am Acad Der*matol. 2000;42:731-734.

Rivers JK. Unusual melanoma types. *Dermatol Clin*. 2002;20:727-733.

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67(6):472-492

15 Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199. Epub 2011 Apr 25.

16Balch CM, Gershenwald JE, et al., “Final Version of 2009 AJCC Melanoma and Staging Classification”, *J Clin Oncol*, 2009; 27:6199-6206.

17 The prognostic impact of the anatomical sites in the 'head and neck melanoma': scalp versus face and neck. de Giorgi V, et al. Melanoma Res. 2012 Aug 23.

18Rogers GS, Braun SM. Prognostic factors. *Dermatol Clin*. 2002;20:647-658.

19 Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. *J Clin Oncol*. 2001;19:3635-3648.

20212223 Flaherty KT, Puzanov I, et al., ”Inhibition of Mutated, Activated BRAF in Metastatic Melanoma”, N Engl J Med, 2010; 363:809-819.

24 Eggermont AMM, “Advances in the Systemic Treatment of Melanoma”, Ann Oncol, 2010; vii330-vii344.

25 Long GV, Flaherty KT, Stroyakovskiy D,et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;.

26 Saranga-Perry V, Ambe C, et al., “Recent Developments in the Medical and Surgical Treatment of Melanoma”, CA Cancer J Clin, 2014; 64:171-185.

27 Palathinkal DM, Sharma TR, et al., “Current Systemic Therapies for Melanoma”, Dermatol Surg, 2014; 40:948-963.

28[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm](https://urldefense.proofpoint.com/v2/url?u=http-3A__www.fda.gov_NewsEvents_Newsroom_PressAnnouncements_ucm469571.htm&d=CwMFAg&c=eBVNo3YqzKy-usbkcQ9Xkw&r=zT6gOanFVMRsFhbEgtUBaHI6xOWHhaoIkWTvRza6n0g&m=EFpcaOB4YLUThzLU-omwdScgXf4K21nFcp8Xn9oFzPU&s=FQg_o3VLbmuLdyFO7LaF3mNdJkDy6EEBdM5K7dtOYxc&e=)

29 Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999). National Cancer Institute, DCCPS, Surveillance Research Program. Cancer Statistics Branch. Released April 2002. Based on November 2001 Submission.

30 Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. *Dermatol Surg*. 1995;21:285-290.

31 Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease progression after local recurrence of melanoma. *Cancer*. 2000;88:1063-1071.

32 Wildemore JK, Schuchter L, Mick R, et al. Locally recurrent malignant melanoma characteristics and outcomes: A single institution study. *Ann Plast Surg*. 2001;46:488-494.

33 Heenan PJ. Local recurrence of melanoma. *Australas J Dermatol*. 1997;38 (Suppl 1):S59-S62.

Colon Cancer

**Endnotes – Colon Cancer**

Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 67(3):177–193

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975_2012/>, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

Cappell M, “The Pathophysiology, Clinical Presentation, and Diagnosis of Colon Cancer and Adenomatous Polyps”, Med Clin N Am, 2005; 89:1-42.

Siegel R, Miller KD, Jemal A, “Cancer Statistics, 2019”, CA Cancer J Clin. 2019;0:1–28

Rudy D, Zdon MJ “Update on Colorectal Cancer”, Am Fam Physician”, 2000; 61:1759-70,1173-4.

Niederhuber JE, Cole CE, et al., “Colon Cancer” in Abeloff MD, Armitage JO et al, eds. *Clinical Oncology*, 3rd ed., 2004, Churchill Livingstone, Elsevier.

Nease DE, Stoffel E, et al., “Colorectal Cancer Screening”, Clin Am Fam Practice, 2004; 6:693-707.

Soreide K, Berg M, et al., "Advances in the Understanding and Treatment of Colorectal Cancer”, Discovery Med, 2011;12:393-404.

Labianca R, Nordlinger B, et al., “Early Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up”, Ann Oncol, 2013; 24(Suppl 6):vi64-vi72.

Giardiello FM, Brensinger JD, Petersen GM, “AGA Technical Review on Hereditary Colorectal Cancer and Genetic Testing”, Gastroenterology, 2001; 121:198-213.

Jasperson KW, Tuohy TM, et al., "Hereditary and Familial Colon Cancer”, Gastroenterol, 2010; 138:2044-2058.

Cummings LC, Cooper GS, “Colorectal Cancer Screening: Update for 2011”, Seminar Oncol, 2011; 38:483-489.

Jessup JM, Goldberg RM, Aware EA, et al. Colon and Rectum. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), AJCC, Chicago 2017. p.251. Corrected at 4th printing, 2018.

Alotaibi AM, Lee JL, Kim J, et al. Prognostic and Oncologic Significance of Perineural Invasion in Sporadic Colorectal Cancer. Ann Surg Oncol 2017; 24:1626.

Kelley RK, Venook AP, “Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?”, Clin Colorectal Cancer, 2011; 10:73-80.

Kopetz S, Tabeernero J, et al., “Genomic Classifier Colprint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors, Oncologist, 2015; 20:127-133.

Dalerba P, Sahoo D, Paik S, et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III

Colon Cancer. N Engl J Med 2016;374:211-22.

Reimers MS, Kuppen PJK, et al., “Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictior of RecurrenceRisk in Stage II and III Rectal Cancer”, J Natl Cancer Inst, 2014; Epub

Szylberg L, Janiczek M, et al., “Large Bowel Genetic Background and Inflammatory Processes in Carcinogenesis – Systematic Review”, Adv Clin Exp Med, 2015; 24:555-561.

Hawk ET, Umar A, Richmond E, Viner JL, “Prevention and Therapy of Colorectal Cancer”, Med Clin North Am, 2005; 89:85-110.

Lavery IC, Lopez-Kostner F, Pelley RJ, Fine RM, “Treatment of Colon and Rectal Cancer”, Surg Clin North Am, 2000; 80:535-69.

Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018; 378:1177.

Meyerhardt J, Mayer RJ, “Systemic Therapy for Colorectal Cancer”, N Engl J Med, 2005; 352:476-87.

Tsao JI, DeSanctis J, Rossi RL, Oberfield RA, “Hepatic Malignancies”, Surg Clin North Am, 2000; 80:603-32.

Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999). National Cancer Institute, DCCPS, Surveillance Research Program. Cancer Statistics Branch. Released April 2002. Based on November 2004 Submission.

26 Chang GJ, Hu CY, Eng C, et al. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009; 27:5938.

Prostate Cancer

**Endnotes – Prostate Cancer**

Cancer Facts & Figures 2001, American Cancer Society, Inc.

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975_2012/>, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

Reiter RE, deKernion JB, “Epidemiology, Etiology, and Prevention of Prostate Cancer” in Walsh PC, Retik AB, Darracott Vaughan E, Wein AJ, eds *Campbell’s Urology*, 8th ed., Saunders Elsevier.

Siegel R, Miller KD, Jemal A, “Cancer Statistics, 2019”, CA Cancer J Clin, 2019;0:1–28.2015; 65:5-29.

Nelson WG, Ballantine Carter H, et al., ”Prostate Cancer” in Abeloff MD, Armitage JO et al, eds. *Clinical Oncology*, 3rd ed., Churchill Livingstone, Elsevier.

Boyle P, Severi G, Giles GG, “The Epidemiology of Prostate Cancer”, Urol Clin North Am, 2003; 30:209-17.

Bratt O, Drevin L, Akre O, et al. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. J Natl Cancer Inst. 2016 Oct;108(10)

PDQ Cancer Genetics Editorial Board , “Genetics of Prostate Cancer (PDQ)”, Published Online, December 10, 2015.

Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; :JCO1800606.

Alibhai MH, “What is Prevalence of Prostate Cancer Among Men with Low Prostate-Specific Antigen/”, N Engl J Med, 2004; 350:2239-46.

Borofsky MS, Makarov DV, “PSA Velocity in Prostate Cancer Screening-the Debate Continues”, Nat Rev Urol, 2011; 8:413-414.

US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913.

Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017;167(7):449-455.

15 Tosoian JJ, Ross AE, et al., “Urinary Biomarkers for Prostate Cancer”, Urol Clin N Am, 2016; 43:17-38.

16 Getzenberg RH, Partin AW, “Prostate Cancer Tumor Markers”, in Wein AJ, Kavoussi LR, et al., eds. Wein: Campbell-Walsh Urology, 10th ed., Saunders Elsevier.

17 Shariat SF, Semjonow A, et al., “Tumor Markers in Prostate Cancer I: Blood Based Markers”, Acta Oncol, 2011;50 (Suppl 1):61-75.

18 Hansen J, Rink M, Assays for Prostate Cancer: Changing the Screening Paradigm?”, Mol Diagn Ther, 2013; 17:1-8.

19 Auprich M, Bjartell A, et al., “Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer”, Eur Urol, 2011; 60:1045-1054.

Wilson SS, Crawford WD, “Screening for Prostate Cancer: Current Recommendations”, Urol Clin N Am, 2004; 31:219-26.

Han M, Gann PH, Catalona WJ, “Prostate-Specific Antigen and Screening for Prostate Cancer”, Med Clin N Am, 2004; 88:245-65.

Hernandez J, Thompson IM, “Diagnosis and Treatment of Prostate Cancer”, Med Clin N Am, 2004; 88:267-79.

Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018; 378:1767..

Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40:244.

Özsoy M, D'Andrea D, Moschini M, et al. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urol Oncol 2018; 36:158.e1.

Stark, JR, Pernier S, et al., “Gleason Score and Lethal Prostate Cancer: Does 3+4 = 4+3?”, J Clin Oncol, 2009; 27:3459-3464.

Dickinson SI, “Premalignant Prostate Lesions: Pathologic Review”, Cancer Control, 2010; 17:214-222.

Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate Cancer – Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017 May 6;67(3):245-253.

Salmasi A, Said J, Shindel AW, et al. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol 2018; 200:564.

Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; :JCO1800606.

D’Amico AV, Crook JC, et al., “Radiation Therapy for Prostate Cancer” in Wein AJ ed in chief Campbell-Walsh Urology, 9th ed., 2007, Philadelphia, Saunders-Elsevier.

Stephenson AJ, Shariat SF, et al., “Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy”, JAMA, 2004; 291:1325-32.

Laufer M, Pound M, Carducci MA, Eisenberger M, “Management of Patients with Rising Prostate-Specific Antigen After Radical Prostatectomy”, Urology, 2000; 55:309-15.

Freedland SJ, Humphreys EB, et al., “Risk of Prostate-Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy”, JAMA, 2005; 294:433-9.

Trock BJ, Han M, et al., “Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs. Observation in Men with Biochemical Recurrence after Radical Prostatectomy”, JAMA, 2008; 299:2760-2769.

Simmons MN, Stephenson AJ, Llein EA, “Natural History of Biochemical Recurrence after Radical Prostatectomy: Risk Assessment for Secondary Therapy”, Eur Urology, 2007; 51:1175-84.

Pazona JF, Han M, et al., “Salvage Radiation Therapy for Prostate Specific Antigen Progression Following Radical Prostatectomy: 10-Year Outcome Estimates”, J Urol, 2005; 174:1282-1286.

Sharifi N, Gulley JL, Dahut WL, “Androgen Deprivation Therapy for Prostate Cancer”, JAMA, 2005; 294:238-44.

Pienta KJ, Smith DC, “Advances in Prostate Cancer Chemotherapy: A New Era Begins”, CA Cancer J Clin, 2005; 55:300-18.

Lam JS, Pisters LL, Belldegrun AS, “Cryotherapy for Prostate Cancer” in Wein AJ ed in chief Campbell-Walsh Urology, 9th ed., 2007, Philadelphia, Saunders-Elsevier.

Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999). National Cancer Institute, DCCPS, Surveillance Research Program. Cancer Statistics Branch. Released April 2009. Based on March 2007 Submission.

Tewari A Raman JD, et al., “Long-Term Survival Probability in Men with Clinically Localized Prostate Cancer Treated Either Conservatively or with Definitive Treatment (Radiotherapy or Radical Prostatectomy)”, Urology, 2006; 68:1268-74.

43 Uchio EM, Aslan M et al., “Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans”, Arch Intern Med, 2010; 170:1390-1395.

44 Porter C, Kodama K, et al., “25-Year Prostate Cancer Control and Survival Outcomes: A 40 Year Radical Prostatectomy Single Institution Series”, J Urology, 2006; 176:569-574.

45 Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33:272.

46 Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol 2015; 33:3379.

48 Meng MV, Carroll PR, “Treatment of Locally Advanced Prostate Cancer” in Wein AJ ed in chief Campbell-Walsh Urology, 9th ed., 2007, Philadelphia, Saunders-Elsevier.

Han M, Partin AW, et al., “Long-Term Biochemical Disease Free and Cancer-Specific Survival Following Anatomic Radical Retropubic Prostatectomy: The 15-Year Johns Hopkins Experience”, Urol Clin N Am, 2001; 28:555-65.

Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016; 375:1415.

Zelefsky MJ, Yamada Y, et al., “Long-Term Results of Conformal Radiotherapy for Prostate Cancer: Impact of Dose Escalation on Biochemical Tumor Control and Distant Metastasis Free Survival Outcomes”, Int J Radiation Oncology Biol Phys, 2008; 71:1028-1033.

Swanson GP, Riggs MW, Earle JD, Haddock MG, “Long-Term Follow-up of Radical Retropubic Prostatectomy for Prostate Cancer”, Eur Urol, 2002; 42:212-6.

53 Khan MA, Han M, et al., “Long-Term Cancer Control of Radical Prostatectomy in Men Younger than 50 Years of Age: Update 2003”, Urology, 2003; 62:86-92.

54 Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 2018; 379:2319.

55 Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109:32.